New Endocrine Society statement with input from other organizations provides guidance for focusing on individual patient life circumstances that can affect their diabetes management.
After a mixed FDA panel review in August, the agency has approved Medtronic s Symplicity Spyral renal denervation system for treatment of hypertension.